Artivion, Inc. has completed its acquisition of Endospan, marking a significant step in the expansion of its aortic disease treatment portfolio. The closing follows the U.S. Food and Drug Administration’s April 2026 PMA approval of Endospan’s NEXUS® Aortic Arch System. The transaction places a newly approved endovascular technology under a global medical device company with an established presence in cardiac and vascular surgery.
A Strategic Acquisition in Aortic Care
Endospan, headquartered in Herzliya, Israel, has focused on developing endovascular solutions for complex aortic arch disease, including aneurysms and dissections. Its NEXUS system is designed as an off-the-shelf option for patients considered high risk for open surgical repair. The acquisition gives Artivion a stronger position in a segment where treatment options have historically been limited and technically demanding.
FDA Approval Strengthens Commercial Potential
The FDA approval of NEXUS is central to the timing and importance of the deal. As the first off-the-shelf endovascular system approved in the United States for aortic arch disease, including chronic aortic dissections, the device addresses a challenging clinical need. Artivion is now preparing for a broader U.S. commercial launch, which could expand access to minimally invasive treatment for selected high-risk patients.
Financial Terms and Market Reach
The acquisition price is $175 million, reduced by offsets related to loans previously provided, with the possibility of up to $200 million in additional payments tied to U.S. commercial performance over the next two years. Artivion has already been connected to the technology through its role as exclusive distributor of the NEXUS system in EMEA since 2019. That existing relationship may support a smoother transition as the company integrates Endospan’s operations and product platform.
International Portfolio Expansion
Outside the United States, Endospan’s technologies are already established across several international markets. Its expanded offering includes off-the-shelf endovascular systems as well as custom-made multibranch configurations, including NEXUS DUO and NEXUS TRE. These products broaden Artivion’s reach across Europe, Asia-Pacific, and Latin America while strengthening its ability to serve a range of aortic arch treatment scenarios.
Broader Platform and Future Pipeline
Artivion said the acquisition completes a three-part aortic arch portfolio that also includes AMDS and ARCEVO LSA. The company views NEXUS not only as a single product but as a platform with potential for future development. Endospan’s pipeline of next-generation arch technologies is expected to support Artivion’s longer-term ambitions in the aortic arch market.
The completion of the Endospan acquisition gives Artivion a differentiated endovascular technology at a pivotal moment, following U.S. regulatory approval for NEXUS. For surgeons and patients, the deal may improve access to a broader set of open, endovascular, and hybrid options for complex aortic disease. With an expanded global footprint and a developing technology pipeline, Artivion is positioning itself as a leading player in the evolving aortic arch treatment market.